| 产品描述: | FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor. |
| 靶点: |
RSK2 |
| 体外研究: |
FMK-MEA treatment (80 mg/kg/day for 16 days by intraperitoneal injection) in highly metastatic M4e cell xenograft nude mice results in a significant attenuation of LN metastasis. FMK-MEA treatment has no effect on the tumor size, and the proliferation rate of the primary tumor[1]. |
| 体内研究: |
FMK-MEA is a water-soluble derivative of fmk. FMK-MEA treatment inhibits RSK2 kinase activity in diverse, highly invasive human cancer cell lines including 212LN, M4e, A549, and SKBR3 cells. Treatment with the RSK-specific inhibitor FMK-MEA significantly attenuates RSK2 activity, as assessed by the phosphorylation levels of Ser-386 and the consequent invasive ability of A549 cells. |
| 参考文献: |
1. Li D, et al. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem. 2013 Nov 8;288(45):32528-38. |
| 保存条件: |
-20°C, 避光,氮气保存 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.503 ml |
12.517 ml |
25.034 ml |
| 5 mM |
0.501 ml |
2.503 ml |
5.007 ml |
| 10 mM |
0.25 ml |
1.252 ml |
2.503 ml |
| 50 mM |
0.05 ml |
0.25 ml |
0.501 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |